STUDY: Novel Serum Biomarkers for Renal Cell Carcinoma
THE MORE STREAMLINED METHOD, using biomarkers, SHOULD REDUCE THE TIME OF RECOGNITION FOR RCC (KIDNEY CANCER)
This study is essential for the forward movement of cancer research. The more streamlined methods, outlined in the summary of the study, should reduce time of recognition for RCC. RCC accounts for approximately 80% of adult kidney cancer case. Its status of being the most lethal of all the genitourinary tumors spurs from the fact that it is often undetected until it has reached an advanced stage. Early detection could lower the percentage of those suffering and dying from RCC.
Dr. Sung Baek and fellow researchers from The Cancer Therapy & Research Center’s Institute of Drug Development identified biomolecular indicators of disease, known as biomarkers, as it relates to renal cell carcinoma (RCC). The materials and methods included the use of mass spectrometry-based proteomics. The result of this study reaffirmed that Serum Amyloid A’s (SAA) role in RCC. It was concluded that there is a need for a redesign of the methods of indication, to further streamline and minimize future RCC biomarker indication time. STUDY DETAILS
Researchers: Dr. Elzbieta Izbicka, Dr. Sung Baek, Dr. David Campos, Dr. Robert Streeper, and Dr. Armando Diaz III, Dr. Ian M. Thompson
Ask your most pressing medical and health questions at JBNI’s Team of Scientists and Physicians at http://jbni.us/forum or http://twitter.com/JBNIherbs. JBNI Genomics and Cancer Proteomics is the Maker of 100% Natural Bioprin. Bioprin is totally gentle on your stomach.